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I 
HUMAN CYTOKINE 




Cardiac surgery with cardiopulmonary bypass triggers an inflammatory 
response involving proinflammatory cytokines such as tumor necrosis 
factor-a, interleukin-6, and interleukin-8. To elucidate the pathophysiology 
of this cytokine response, we explored the possible differences in cytokine 
responses between patients undergoing heart transplantation and those 
undergoing coronary artery bypass grafting. Plasma levels of tumor 
necrosis factor-a, interleukin-6, interleukin-8, and interleukin-10 were 
measured in eight patients undergoing heart transplantation (mean age 44 
years) and eight patients undergoing coronary artery bypass grafting 
(mean age 61 years). Duration of cardiopulmonary bypass and ischemic 
time were both longer in the heart transplantation group than in the 
coronary artery bypass grafting group (133 -+ 26 min vs 100 _ 31 min, p < 
0.05. and 130 - 47 min vs 58 + 21 min. p < 0.005, respectively). Samples 
were collected before heparin administration, at aortic crossclamping and 
declamping, and at 0.5, 1, 1.5, 2, 4, 12, and 24 hours after declamping. 
Tumor necrosis factor-a levels were significantly higher 30 minutes after 
aortic declamping in the heart transplantation group than in the coronary 
artery bypass grafting group (68 - 30 vs 18 +- 5 pg/ml, p < 0.05). 
Interleukin-6 and interleukin-8 levels were also significantly higher 90 
minutes after declamping in patients undergoing hearl transplantation 
than in those undergoing coronary artery bypass grafting (310 - 63 vs 
169 - 24 pg/ml, p < 0.05, and 73 - 17 vs 24 --- 5 pg/ml, p < 0.01. 
respectively). Furthermore. interleukin-6 and interleukin-8 values 90 min- 
utes after declamping were significantly correlated with the ischemic time 
(r = 0.72 and r = 0.82, respectively, bothp < 0.05). Interleukin-10 levels in 
both groups rose to reach a peak value of around 115 pg/ml 1 hour after 
dedamping. Patients undergoing heart transplantation exhibited a second 
peak of tumor necrosis factor-a, interleukin-8, and interieukin- 10 levels 12 
hours after declamping, probably related to the administration Of rabbit 
antihuman thymocyte immunoglobulin (Thymoglobuline) 3 hours after 
declamping. Interleukin-6 levels decreased more significantly 12 and 24 
hours after declamping in patientS undergoing heart transplantation, 
probably related to methylprednisolone therapy. In conclusion, cardiopul- 
monary bypass is associated with the production of both proinflammatory 
and antiinflammatory c tokines, The production of pr0inflammatory c to- 
kines in patients undergoing heart transplantation is higher than that in pa- 
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tients undergoing coronary artery bypass grafting, and this increase could 
be related to the longer duration of ischemia in the former group. The later 
course of cytokine levels after heart transplantation may be further 
influenced by immunosuppressive therapy. (J TrIORAC CARDIOVASC SURG 1996; 
111:469-77) 
C ardiac surgery with cardiopulmonary bypass (CPB) is associated with a systemic inflammatory 
response that can lead to postoperative multiorgan 
dysfunction. 1'2 These deleterious effects of CPB 
may be caused by the exposure of blood to the 
extracorporeal circuit and by postischemic reperfu- 
sion of the heart and lungs, resulting in complement 
activation and release of oxygen free radicals and 
other mediators. >6 Attention has been focused re- 
cently on the roles of cytokines uch as interleukin-6 
(IL-6) and interleukin-8 (IL-8) in the inflammatory 
injury seen after CPB. 7-13 The release of tumor 
necrosis factor-c~ (TNF- a) has also been reported, 
although less consistently. 7' 9, 12, 14-17 
Clinical investigations to date have included only 
those patients undergoing elective coronary artery 
bypass grafting (CABG), valvular surgery, or correc- 
tion of congenital defects, but the cytokine response 
after heart transplantation (HTx) may also be of 
interest. The early phase of HTx presents some 
important differences from CABG, including longer 
duration of acute ischemia starting from aortic 
crossclamping on the donor heart, so a stronger 
cytokine response might be expected to be elicited. 
Interleukin-10 (IL-10) has recently been reported 
as an antiinflammatory cytokine that deactivates 
both monocytes and macrophages and is therefore 
likely to reduce the release of TNF-a, IL-6, and 
iL_8.1s, 19 IL-10 is also produced during human 
sepsis20 and could be involved in controlling the 
post-CPB inflammatory response. 
We performed a prospective descriptive pilot 
study to examine the plasma levels of TNF-c~, IL-6, 
IL-8, and IL-10 during and after HTx and CABG. 
Patients and methods 
The study was approved by the local ethics committee, 
and informed verbal consent was obtained from each 
patient. Eight consecutive patients undergoing HTx and 
eight consecutive patients undergoing elective CABG for 
ischemic heart disease were studied. Clinical characteris- 
tics of both groups of patients are shown in Table I. All 
patients received a similar balanced anesthetic regimen, 
including sufentanil and midazolam. Curarization was 
achieved with pancuronium. Cefamandol (Mandol) was 
given intravenously for antimicrobial prophylaxis at a 
Table I. Cl in ica l  character is t ics  
HTx group CABG group 
(n = 8) (n = 8) 
Sex ratio (male/female) 7:1 6:2 
Age (yr) 
Mean -+ SD* 44 ± 18 61 _+ 9 
Range 7-65 47-73 
Body surface area 1.76 _+ 0.39 1.87 _+ 0.23 
(m2; mean ± SD) 
Diagnosis DC = 6, IC = 2 IHD 
CPB time (rain) 
Mean ± SD* 133 ± 26 100 _+ 31 
Range 91-166 37-130 
Crossclamp time (rain) 
Mean ± SD 79 ± 16 58 _+ 21 
Range 58-101 22-82 
Ischemic time (min) 
Mean ± SD? 130 _+ 47 58 ± 21 
Range 55-199 22-82 
DC, Dilated cardiomyopathy; IC, ischemic cardiomyopathy; IHD, ischemic 
heart disease. 
*p < 0.05 between groups. 
tp < 0.005 between groups. 
dosage of 2 gm at induction of anesthesia followed by 2 
gm every 6 hours for 48 hours. All patients received 
aprotinin (Trasylol) at a dosage of 280 mg intravenously 
within 30 minutes of the beginning of the operation, 280 
mg infused by pump at the start of CPB, and 70 rag/hour 
intravenously during CPB. Patients undergoing CABG 
received no corticosteroids before or during the opera- 
tion. Those undergoing HTx received azathioprine (Imu- 
ran) at a dosage of 3 to 4 mg/kg after induction of 
anesthesia and rabbit antihuman thymocyte immunoglob- 
ulin (Thymoglobuline) at a dosage of 1 mg/kg intrave- 
nously about 3 hours after aortic declamping, as well as 
methylprednisolone (Solu-Medrol) 90 minutes after 
declamping (500 mg intravenously) and every 8 hours 
thereafter (125 mg) during the first postoperative day. 
Recipient selection for HTx, donor criteria, and organ 
procurement have been described elsewhere, l All pa- 
tients in the HTx group underwent orthotopic ardiac 
transplantation by the standard Lower and Shumway 
technique, a2 
The extracorporeal circuit, consisting of a roller pump 
(Stockert Instrumente GmbH, Munich, Germany) and a 
membrane oxygenator (Univox-IC, Baxter Healthcare 
Corp., Bentley Division, Irvine, Calif.) was uniformly 
employed. Pump flow was kept at 2.0 to 2.5 L/min/m 2. 
Heparin (loading dose of 3 mg/kg) was infused to main- 
tain an activated clotting time of more than 480 seconds 
during CPB. Cold crystalloid cardioplegia containing a 
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Fig. 1. Plasma TNF-c~ levels in patients undergoing HTx (n = 8) or CABG (n = 8).Asterisk indicatesp <
0.05 vs CABG group; double asterisk indicates p < 0.002 vs CABG group. Data are mean _+ SEM. B/-/, 
Before heparin administration; C-C, crossclamping; DC, declamping; TG, rabbit antihuman thymocyte 
immunoglobulin. Shaded bars indicate steroid administration i  HTx group. 
Ringer's lactate solution with potassium and magnesium 
chloride as well as sodium bicarbonate, supplemented by
slush topical hypothermia, was used for cardiac preserva- 
tion in all cases. After each distal anastomosis in the 
CABG group, 80 to 120 ml additional cold cardioplegia 
was delivered through the vein graft. Patients in the HTx 
group were cooled to between 26 ° and 28 ° C and patients 
in the CABG group were cooled to 30 ° C. Rewarming 
began during the aortic anastomosis in the HTx group and 
during the final distal anastomosis n the CABG group. 
The proximal anastomoses were completed in the latter 
group with the aid of a tangential clamp after removal of 
the crossclamp. On discontinuation of CPB, heparin was 
neutralized with protamine sulfate in a 2:3 ratio with respect 
to total dosage of heparin. Inotropic support consisting of a 
dobutamine infusion was provided at the end of operation in 
all patients in the HTx group and in five patients in the 
CABG group. Temporary pacing was also used in all pa- 
tients in the HTx group and in two patients in the CABG 
group. 
Blood was collected from peripheral arterial lines or the 
arterial side of the pump circuit on an event-based 
schedule as follows: (1) just before heparin administra- 
tion, (2) immediately after aortic crossclamping, (3) im- 
mediately after aortic declamping, and at (4) 30 minutes, 
(5) 60 minutes, (6) 90 minutes, (7) 2 hours, (8) 4 hours, (9) 
12 hours, and (10) 24 hours after aortic declamping. All 
samples were anticoagulated with ethylenediaminetet- 
raacetic acid, immediately cooled to 4 ° C, and centrifuged 
within 30 minutes (3000 g for 10 minutes at 4 ° C). Plasma 
was stored at -20  ° C until assay. 
TNF-c~, IL-6, IL-8, and IL-10 plasma levels were deter- 
mined by means of commercially available nzyme-linked 
immunosorbent assays (Medgenix Diagnostics SA, Fleu- 
rus, Belgium). No adjustment was made for hemodilution. 
The sensitivities were 15 pg/ml for TNF-c~, 30 pg/ml for 
IL-6, 7 pg/ml for IL-8, and 11 pg/ml for IL-10. 
Data are expressed as mean _+ standard error of the 
mean (SEM) unless otherwise indicated. At each time 
point, the Mann-Whitney U test was used for statistical 
comparison of cytokine levels between HTx and CABG 
groups. The Spearman correlation coefficient test was used 
to explore the correlation between cytokine levels and isch- 
emic time. Ap  value < 0.05 was considered to be significant. 
Resu l ts  
Patients.  Table I summarizes clinical characteris- 
tics of the patients tudied. Al l  patients urvived the 
hospital  stay. Al l  patients in the CABG group but 
one, who received only two venous grafts, received 
three to four bypass grafts, including one internal 
mammary  artery grafted onto the left anter ior  de- 
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Fig. 2. Plasma IL-6 levels in patients during and after HTx (n = 8) and CABG (n = 8). Asterisk indicates 
p < 0.05 vs CABG group. Data are mean -+ SEM. BH, Before heparin administration; C-C, crossclamping; 
DC, declamping; TG, rabbit antihuman thymocyte immunoglobulin. Shaded bars indicate steroid admin- 
istration in HTx group. 
scending coronary artery. As expected, duration of 
CPB and ischemic time (starting from aortic cross- 
clamping on the donor heart in the HTx group) was 
longer in the HTx group than in the CABG group 
(Table I). No patient required reexploration for 
bleeding after operation. 
Cytokines. TNF-a (Fig. 1). TNF-o~ levels in- 
creased immediately after aortic declamping inboth 
groups and reached their peak value 1.5 to 2 hours 
after reperfusion. TNF-a levels 30 minutes after 
declamping were significantly higher in the HTx 
group than in the CABG group. In the HTx group 
there was a second peak of TNF-a levels 12 hours 
after declamping, after administration f rabbit an- 
tihuman thymocyte immunoglobulin. 
IL-6 (Fig. 2). In both groups of patients, IL-6 
levels increased after aortic declamping. IL-6 levels 
rose higher in the HTx group but decreased earlier 
in these patients. IL-6 levels 90 minutes after 
declamping were significantly correlated with isch- 
emic time (Fig. 3). 
IL-8 (Fig. 4). The IL-8 levels increased in both 
groups after aortic declamping, but more so in the 
HTx group than in the CABG group. IL-8 levels 90 
minutes after declamping were significantly corre- 
lated with ischemic time (Fig. 3). Patients in the 
HTx group also showed asecond peak in IL-8 levels 
12 hours after reperfusion. 
IL-10 (Fig. 5). Plasma IL-10 levels increased in 
both groups during the 2 hours after aortic declamp- 
ing. The degree of increase in IL-10 levels was 
similar in the two groups of patients. Interestingly, 
there was also a second peak release of IL-10 in the 
HTx group 12 hours after declamping, probably 
influenced by immunosuppressive th rapy. 
Discussion 
This study documented the release of proinflam- 
matory cytokines, including TNF-o~, IL-6, and IL-8, 
in patients undergoing HTx and CABG. It also 
showed the release of IL-10 under these conditions. 
The release of cytokines during CPB has been 
documented recently by several groups of investiga- 
tors. 7-17 TNF-a is a potent proinflammatory c to- 
kine susceptible to induce hypotension and organ 
damage. TNF-a levels were not detectable in many 
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Fig. 3. Correlation between plasma IL-6 and IL-8 levels 90 minutes after aortic declamping and ischemic 
times in the 16 patients. 
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Fig. 4. Plasma IL-8 levels in the HTx (n = 8) and CABG (n = 8) groups. Asterisk indicates p < 0.05 vs 
CABG group; double asterisk indicates p < 0.01 vs CABG group. Data are mean + SEM. BH, Before 
heparin administration; C-C, crossclamping; DC, declamping; TG, thymocyte immunoglobulin. Shaded bars 
indicate steroid administration i  HTx group. 
previous tudies, 7'9, 12, 15-17 but were measured in a 
few.14, 23, 24 These differences may be caused in part 
by the different kits or different methods of mea- 
surement used. We found TNF-~ levels to be de- 
tectable in both groups of patients after declamping, 
but this increase was quite modest. Patients in the 
HTx group had a somewhat greater release of 
TNF-a, but the difference was significant only at 30 
minutes after declamping. IL-6 does not have major 
hemodynamic effects but does play an important 
role in the acute-phase r sponse, primarily concern- 
ing the liver. It has been suggested that IL-6 may be 
a marker whose levels are directly related to the risk 
of postoperative complications. 13 Several investiga- 
tors reported that IL-6 levels already increased after 
protamine administration, 7 at the end of operation, s 
and in the first hour after declamping. ~2 IL-8 does 
not have significant hemodynamic effects, but it 
plays an important role in leukocyte activation. 12 It 
has also been suggested that IL-8 may exert protec- 
tive effects by preserving endothelial function, re- 
ducing neutrophil infiltration of the necrotic myo- 
cardium, and reducing myocardial necrosis; it would 
thus provide a significant degree of endothelial and 
myocardial protection against reperfusion injuryY 
It is now recognized, however, that IL-8 plays a 
critical role in multiorgan failure after CPB, 13 as it 
does in septicemia, 26 and may also contribute to 
myocyte reperfusion injury during human HTx. 27 
Our data confirm previous investigations reporting 
the release of IL-8 during and after CPB 9-12' 17 or 
after reperfusion. 23' 24, 27 
In addition, our data also provide some important 
information regarding the mechanisms involved in 
the release of these proinflammatory c tokines. This 
is so for two reasons. First, the comparison of the 
cytokine release in patients after HTx and after 
CABG revealed that IL-6 and IL- 8 levels, as well as 
TNF-~ levels, were significantly higher after 
declamping in the HTx group. Moreover, IL-6 and 
IL-8 levels 90 minutes after declamping significantly 
correlated with ischemic time, suggesting that the 
degree of IL-6 and IL-8 expression is strongly 
related to the degree of ischemia. Recently, Hen- 
nein and associates 23also noted that aortic cross- 
clamp time was an independent predictor of post- 
operative TNF-c~, IL-6, and possibly IL-8 levels. 
Differences in temperature may also be important. 9 
On the one hand, Menasch6 and colleagues 24re- 
ported that TNF- c~ and IL-6 levels were higher 2 
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Fig. 5. Plasma IL-10 levels in patients undergoing HTx (n = 8) and CABG (n = 8).Asterisk indicatesp <
0.05 vs CABG group. Data are mean _+ SEM. BH, Before heparin administration; C-C, crossclamping; DC, 
declarnping; TG, thymocyte immunoglobulin. Shaded bars indicate steroid administration in HTx group. 
hours after CPB after normothermic (37 ° C) than 
after hypothermic (28 ° to 30 ° C) heart operations, 
indicating that cytokine release may be temperature 
dependent. On the other hand, Frering and associ- 
ates iv found that changes in temperature did not 
induce the production of IL-6 and IL-8. In our 
study, however, the differences in cytokine levels 
between the HTx group and the CABG group could 
hardly be explained by the minor difference in 
temperature at the end of the two procedures. As 
expected, patients in the HTx group were also 
younger than those in the CABG group, but there is 
no good evidence that the cytokines release are 
significantly influenced by age. Aprotinin may have 
antiinflammatory effects, but it was given to all 
patients and thus does not account for the differ- 
ences between groups. 
Second, our sampling times were somewhat dif- 
ferent han in those used in previous tudies because 
we selected time points by aortic declamping only, 
regardless of the duration of CPB. We observed that 
the cytokine release during ischemia was insignifi- 
cant but became striking after aortic declamping. As 
suggested by some experiments, 28 it appears that 
reperfusion of the heart and lungs at the time of 
declamping could represent a major cause of proin- 
flammatory cytokine release in patients undergoing 
CPB. TNF-a, IL-6, and IL-8 were hardly released at 
the end of ischemic period, even when it was long, but 
were released later, which strongly suggests hat reper- 
fusion is an important trigger of this cytokine response. 
Another interesting aspect of our study was the 
observation during CPB of a significant release of 
IL-10, which is considered an antiinflammatory cy-
tokine capable of inhibiting some proinflammatory 
cytokines, including TNF-a, IL-6, and IL-8.18-2° 
Interestingly, in contrast to production of proinflam- 
matory cytokines, IL-10 production was unrelated to 
the duration of ischemia. It is noteworthy that 
cytokines are likely to act both individually and 
within a network of interrelated and interacting 
signals and may be much more detrimental in 
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combination.13, 28,29 For instance, TNF-a and IL-1 
can exert their effects directly as well as through the 
expression of IL-6, and even IL-8, by many cell 
types.29,30 Furthermore, it has been suggested re- 
cently that TNF-oz is involved both in vitro 31 and in 
vivo 3a in the induction of IL-10, a cycle that provides 
a negative feedback to TNF-~ production. 
In the HTx group, cytokine response also ap- 
peared to be influenced by immunosuppressive th r- 
apy. Obviously, a control HTx group without immu- 
nosuppressive therapy could not be considered, so 
the effects of immunotherapy can be evaluated only 
by comparison with the CABG group. In the HTx 
group, TNF-oL levels dramatically increased 12 hours 
after CPB, probably under the influence of the 
rabbit antihuman thymocyte immunoglobulin ad- 
ministration and despite the earlier administration 
of steroids known to inhibit the release of TNF-o~. 14 
IL-6 levels decreased more  rapidly than after 
CABG, probably under the influence of steroids. 33 
IL-8 levels also presented a second peak, probably 
also related to the administration of rabbit antihu- 
man thymocyte immunoglobulin and perhaps medi- 
ated by TNF-oz. As observed for TNF-o~ and IL-8, 
IL-10 levels showed a second peak in the HTx 
group; this was probably also induced by immuno- 
suppressive therapy. IL-10 may be involved in the 
immunosuppression of transplant recipients, as sup- 
ported by the observation that cyclosporine A can 
dramatically enhance ndotoxin-induced IL-10 pro- 
duction. 34 
In conclusion, the elevation of the levels of proin- 
flammatory cytokines TNF-o~, IL-6, IL-8 are shown 
to be more pronounced in patients undergoing HTx 
than those undergoing CABG, and these differences 
are related at least in part to a longer duration of 
ischemia in the HTx group. Our study also indicates 
that antiinflammatory c tokine IL- 10 is released 
during and after CPB, and that the degree of release 
of IL-10 is not related to the duration of ischemia. In 
the HTx group; the cytokine responses may also 
have been influenced by immunosuppressive ther- 
apy. Whether anticyt0kine strategies aiming at a 
reduction in reperfusion injury can reduce compli- 
cations after CPB is an intriguing question that 
remains open. 
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